The MO HealthNet Division (MHD) is responding to an outbreak of respiratory disease caused by a novel (new) coronavirus. The virus has been named "SARS-CoV-2" and the disease it causes has been named "coronavirus disease 2019" (abbreviated "COVID-19").
During this event, the MHD will maintain the current clinical criteria for the Sedative Hypnotic Preferred Drug List. The MHD had previously planned to implement significant utilization management changes to the Sedative Hypnotic Preferred Drug List. However, in order to minimize provider burden and disruption to patient care during the COVID 19 pandemic, the MHD will delay implementation of the new criteria until July 2020.
A copy of the current criteria, and future criteria, is available on the MO HealthNet Pharmacy Clinical Edits and Preferred Drug Lists website, located at: https://dss.mo.gov/mhd/cs/pharmacy/pages/clinedit.htm.